Skip to main content
Clinical Trials/NCT03115125
NCT03115125
Unknown
Not Applicable

Descriptive Study of the Evolution in Proportion of Regulatory B Lymphocytes in Patients Hospitalized in Intensive Care for Severe Sepsis

Centre Hospitalier Universitaire, Amiens1 site in 1 country50 target enrollmentApril 20, 2016
ConditionsSevere Sepsis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Severe Sepsis
Sponsor
Centre Hospitalier Universitaire, Amiens
Enrollment
50
Locations
1
Primary Endpoint
Variation in the proportion of circulating Breg compared to total B lymphocytes in the included cohort of patients
Last Updated
9 years ago

Overview

Brief Summary

Severe sepsis and septic shock are the most severe forms of sepsis (which associates a systemic inflammatory response with infection). These are serious pathologies with a lethality estimated at almost 40% at 28 days (after the onset of sepsis).

After a first pro-inflammatory phase, a second compensatory phase called Compensatory Anti-Inflammatory Response Syndrome (CARS) takes place quickly. Patients then show signs of immunosuppression and profound alterations in immune functions. It is during this phase that the vast majority of deaths occur, far from the onset of the shock, which is related to the inability of the immune system to eliminate the initial infectious agent and / or a greater susceptibility Important to develop secondary infections (nosocomial infection, latent virus reactivation ...).

The CARS phase has been the subject of studies focusing on measuring the plasma concentration of anti-inflammatory cytokines (such as Interleukin (IL) -10), the percentage of regulatory T lymphocytes (Treg), Or the percentage of monocytic expression of HLA-DR in septic patients.

The investigator proposes to carry out the first study on a newly described regulatory lymphocytic subpopulation: regulatory B lymphocytes (Breg) from a quantitative and functional point of view in severe septic states.

Registry
clinicaltrials.gov
Start Date
April 20, 2016
End Date
May 19, 2017
Last Updated
9 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult patients with severe sepsis or septic shock diagnosed less than 24 hours (defined as D0) and hospitalized in the medical resuscitation department of the Amiens-Picardie University Hospital.
  • The definitions of severe sepsis and septic shock are the result of the consensus of the Société de Réanimation de Langue Française dating from 2005:
  • Sepsis refers to a systemic inflammatory response syndrome (SIRS) in the presence of suspected or identified infection. Sepsis is said to be severe when lactate\> 4 mmol / L or arterial hypotension prior to filling or organ dysfunction is present (one is sufficient): hypoxemia with a PaO2 / FIO2 \<300 ratio, renal failure with Hepatic insufficiency with INR\> 4 or bilirubin\> 78 μmol / l, thrombocytopenia (platelets \<100 000 / mm3) and hepatic insufficiency\> 176 μmol / l, coagulation disorders with INR\> 1.5 Disorders of higher functions with a Glasgow Coma Score \<
  • Finally, septic shock is defined as a severe sepsis condition with persistent hypotension despite a well-conducted vascular filling (20-40 ml / kg isotonic saline).

Exclusion Criteria

  • Patient with active neoplasia, immune deficiency, autoimmune disease or autoimmune disease.
  • Patient under tutorship or curatorship
  • Taking an immunomodulatory or immunosuppressive treatment at the time of the study or the year prior to hospitalization for sepsis.
  • Antecedent or haematopoietic graft in progress.
  • Pregnancy in progress.
  • Known history of infection with human immunodeficiency virus (HIV) type 1 or 2 or with hepatitis B or C virus
  • Patient with agranulocytosis (defined as neutrophils \<0.5 G / L).

Outcomes

Primary Outcomes

Variation in the proportion of circulating Breg compared to total B lymphocytes in the included cohort of patients

Time Frame: 28 days

Study Sites (1)

Loading locations...

Similar Trials